IL2RA and myeloid sarcoma: In addition, Mendelian randomization study showed that there was a causal relationship between the genetic susceptibility of IL2RA and MS, whose targeted drug daclizumab had distinct efficacy in reducing gadolinium-enhanced lesions and annual recurrence rate (40).